Wedbush Reaffirms Outperform Rating for Keros Therapeutics (NASDAQ:KROS)

Keros Therapeutics (NASDAQ:KROS)‘s stock had its “outperform” rating reiterated by investment analysts at Wedbush in a report issued on Thursday, RTT News reports. They currently have a $84.00 target price on the stock. Wedbush’s price objective points to a potential upside of 24.35% from the company’s previous close. Wedbush also issued estimates for Keros Therapeutics’ Q3 2024 earnings at ($1.31) EPS, Q4 2024 earnings at ($1.36) EPS, FY2024 earnings at ($5.14) EPS, Q1 2025 earnings at ($1.41) EPS, Q2 2025 earnings at ($1.43) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($1.27) EPS, FY2025 earnings at ($5.32) EPS, FY2026 earnings at ($5.16) EPS, FY2027 earnings at ($5.57) EPS and FY2028 earnings at ($4.66) EPS.

KROS has been the topic of several other research reports. Cantor Fitzgerald assumed coverage on Keros Therapeutics in a research note on Thursday, October 24th. They set an “overweight” rating on the stock. Scotiabank assumed coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Guggenheim began coverage on shares of Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective for the company. Bank of America lowered their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a report on Thursday, September 12th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Trading Up 1.7 %

Keros Therapeutics stock traded up $1.10 during trading on Thursday, reaching $67.55. The company had a trading volume of 77,517 shares, compared to its average volume of 368,025. The firm’s 50-day simple moving average is $56.87 and its 200 day simple moving average is $51.89. Keros Therapeutics has a 52 week low of $27.31 and a 52 week high of $73.00. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of -13.14 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 44.73% and a negative net margin of 62,012.55%. The company’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period last year, the company earned ($1.33) earnings per share. On average, analysts predict that Keros Therapeutics will post -4.9 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Carl L. Gordon sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the transaction, the director now directly owns 119,522 shares of the company’s stock, valued at approximately $5,260,163.22. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 22.90% of the company’s stock.

Institutional Trading of Keros Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in KROS. KBC Group NV raised its holdings in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. bought a new position in shares of Keros Therapeutics in the 3rd quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics during the 2nd quarter worth $128,000. Finally, Ameritas Investment Partners Inc. grew its stake in Keros Therapeutics by 14.5% in the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock valued at $169,000 after purchasing an additional 324 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.